Tivantinib
作者：齊岳
發布時間：2023-08-30
09:00:41
點擊數：
產品名稱：Tivantinib
產品描述：
| 產品描述 | Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. |
| 靶點活性 | c-Met:0.355 μM(Ki) |
| 體外活性 | 用ARQ-197處理的所有三種異種移植物模型顯示生長減少：HT29模型中66％,MKN-45模型中45％,MDA-MB-231模型中79％.口服給藥200 mg/kg ARQ-197處理HT29,MKN-45和MDA-MB-231三種移植瘤模型,沒有顯著的體重變化.藥效學方面,ARQ-197強效抑制人類結腸移植瘤HT29中c-Met的磷酸化,單獨口服200 mg/kg ARQ-19724小時后,c-Met自磷酸化強烈下降.總之,ARQ-197抑制ARQ-197抑制c-Met依賴性異種移植人類的生長. |
| 體內活性 | ARQ-197具有抗活性,抑制A549,DBTRG和NCI-H441細胞增殖,IC50分別為0.38,0.45,0.29 μM。用ARQ-197處理,導致MAPK信號級聯反應的磷酸化減少及預防侵入和遷移。此外,在沒有內源性c-Met表達的細胞系NCI-H661中c-Met的異位表達導致其獲得侵襲性表型,也被ARQ-197抑制。ARQ-197抑制人類重組c-Met,具有恒定的Ki值,為355 nM。ARQ-197抑制c-Met磷酸化,且阻斷下游c-Met信號通路。盡管增加濃度的ARQ-197不會顯著影響ATP的Km,但c-Met暴露于0.5 μMARQ-197會使c-Met的Vmax降低約3倍。ARQ-197降低Vmax而不影響ATP的Km值說明ARQ-197抑制c-Met是非ATP競爭抑制,也說明ARQ-197具有高度激酶選擇性。ARQ-197抑制組成型和配體介導的c-Met自磷酸化,并且進而抑制c-Met活性,繼而導致抑制下游c-Met效應物。在表達c-Met的人類*細胞（包括HT29,MKN-45和MDA-MB-231細胞）中ARQ-197誘導胱天蛋白酶依賴性細胞凋亡增加。 |
| 激酶實驗 | c-Met SDS-PAGE in vitro kinase assay: Recombinant c-Met protein (100 ng) is preincubated with increasing concentrations of ARQ-197 for 30 minutes at room temperature. Following preincubation, 100 μM of poly-Glu-Tyr substrate and various concentrations of ATP containing 5 μCi of [γ-32P]ATP are added to the reaction mixture. The reaction is incubated for 5 minutes at room temperature and then stopped by the addition of 5 μL of SDS-polyacrylamide gel, reducing sample buffer. The samples are then loaded onto a 7.5% acrylamide gel and SDS-PAGE is performed. The phosphorylated poly-Glu-Tyr substrates are ultimately visualized by autoradiography. c-Met activity is quantified by densitometry. |
| 細胞實驗 | HT29, MKN-45, and MDA-MB-231 cells are seeded in black 96-well plates at 5 × 103 cells per well overnight in a medium with 10% FBS. The next day, cells are treated with increasing concentrations of ARQ-197 (0.03-10 μM) for 24, 32, and 48 hours at 37 °C. After ARQ-197 treatment, the drug-containing medium is removed and cells are incubated for at least 10 minutes in a labeling solution (10 mM HEPES, 140 mM NaCl, and 6 mM CaCl2) containing 2 μg/mL Hoescht 33342 (blue channel), 500-times diluted Annexin V-FITC (green channel), and 1 μg/mL propidium iodide (red channel). High-content image acquisition and analysis are carried out. The program is set to take four images per well. The exposure time is set at 16.7 ms/10% gain, 500 ms/35% gain, and 300 ms/30% gain for the 4,6-diamidino-2-phenylindole, FITC, and rhodamine channels, respectively. Images are processed and the numbers of positive cells for each channel and each condition are determined. In addition, HT29 cells are treated with increasing concentrations of ARQ-197 for 32 hours in the absence or the presence of 25, 50, and 100 μM ZvAD-FMK (irreversible general caspase inhibitor), and the same procedures are undertaken. All experiments are done in triplicate. To determine whether the apoptotic effect is due to c-Met inhibition, the effect of ARQ-197 when glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and c-Met are knocked down using siRNA is investigated. HT29, MKN-45, and MDA-MB-231 cells are transfected with a nontargeted control siRNA, a gapgh-targeted control siRNA, or a met-targeted siRNA. After 3 days, c-Met, GAPDH, and β-actin expression levels are determined using specific antibodies. To determine if the effect is caspase dependent, HT29, MKN-45, and MDA-MB-231 cells are transfected with a met-targeted siRNA for 2 days and incubated in the absence or the presence of increasing concentrations of ZvAD-FMK for 1 additional day.A nontargeted siRNA and a gapgh-targeted siRNA (siRNA GAPDH) are also transfected in parallel, as controls. Cells are then stained with Annexin V-FITC and propidium iodide, and the percentage of apoptotic cells is determined.(Only for Reference) |
| 別名 | ARQ 197 |
| 分子量 | 369.42 |
| 分子式 | C23H19N3O2 |
| CAS No. | 905854-02-6 |
存儲
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
溶解度
DMSO: 68 mg/mL (184.1 mM)
Ethanol: <1 mg/mL
H2O: <1 mg/mL
( < 1 mg/mL refers to the product slightly soluble or insoluble )
聯系我們：
郵箱：2519696869@qq.com
QQ: 2519696869
電話：18066853083
微信：18066853083
公司介紹：
西安齊岳生物科技有限公司是集化學科研和定制與一體的高科技化學公司。業務范圍包括化學試劑和產品的研發、生產、銷售等。涉及產品為通用試劑的分銷、非通用試劑的定制與研發，涵蓋生物科技、化學品、中間體和化工材料等領域。
主營產品：COF、MOF單體系列：三蝶烯衍生物、金剛烷衍生物、四苯甲烷衍生物、peg、上轉換、石墨烯、光電材料、點擊化學、凝集素、載玻片、蛋白質交聯劑、脂質體、蛋白、多肽、氨基酸、糖化學等。
